GAPDH and Huntington disease: ThesiRNA technology was used to show that the inhibition of GAPDH expression leadsto a 45–50% reduction in the aggregation of mutant huntingtin, with a repeat of103 glutamine residues in a model of Huntington’s disease (HD).